U.S. Construction Stock News

NYSE:GPN
NYSE:GPNDiversified Financial

How Investors May Respond To Global Payments (GPN) Profit Slide Paired With Steady Dividend Commitment

Global Payments Inc. reported past second-quarter 2026 results showing sales of US$3,320.79 million but net income of just US$12.97 million, alongside sharply lower earnings per share compared with a year earlier. Despite the weaker profitability and a net loss of about US$1.79 billion over the first half of 2026, the board still approved a US$0.25 per share dividend payable on September 25, 2026, underscoring a commitment to ongoing shareholder payouts. Next, we’ll examine how the weaker...
NYSE:OPY
NYSE:OPYCapital Markets

Is Oppenheimer Holdings (OPY) Fully Valued Following Strong Q2 Earnings?

Why Oppenheimer Holdings Stock Is Back in Focus After Q2 Results Oppenheimer Holdings (OPY) moved back onto investor watchlists after reporting second quarter 2026 earnings that showed higher revenue and net income versus a year earlier, alongside an affirmed quarterly dividend. See our latest analysis for Oppenheimer Holdings. The 1 day share price return of 1.47% to US$114.81 came after Oppenheimer Holdings reported higher second quarter revenue and earnings. This follows a 90 day share...
NYSE:VVV
NYSE:VVVSpecialty Retail

Valvoline (VVV) Is Down 10.0% After Raising 2026 Revenue Guidance Despite Weaker Year‑To‑Date Profits

In August 2026, Valvoline Inc. reported its third-quarter results, with sales rising to US$544.6 million and net income reaching US$64.5 million, while also posting higher basic and diluted earnings per share from continuing operations than a year earlier. Despite stronger third-quarter performance, the company’s net income for the first nine months fell to US$76.5 million even as sales increased to US$1.51 billion, highlighting a contrast between recent quarterly momentum and weaker...
NYSE:IVZ
NYSE:IVZCapital Markets

Invesco (IVZ) Stock Still Looks Below Fair Value Despite 133% Run

Invesco stock has delivered a strong 133.2% return over the past three years, while the intrinsic value estimate from the Excess Returns model points to upside and the market multiple view suggests the shares trade on the expensive side. That split leaves investors weighing a mixed valuation picture rather than a clear bargain or obvious overpricing. Over the past three years, Invesco has returned 133.2%, which puts recent gains at the center of any valuation call on the stock. Expectations...
NYSE:MPC
NYSE:MPCOil and Gas

Marathon Petroleum (MPC) Stock Looks Below Fair Value While Cash Flow Looks Fair

Marathon Petroleum stock has delivered a very large 5 year return, yet the latest valuation checks suggest the current share price around US$348 is closer to fair value than a clear bargain based on the Discounted Cash Flow (DCF) intrinsic value estimate and the market multiples. Over the past 5 years, Marathon Petroleum has returned roughly 7x an initial investment. This puts extra focus on whether recent gains are already pricing in much of the good news. The sharp improvement in refining...
NYSE:AMR
NYSE:AMRMetals and Mining

Is Alpha Metallurgical Resources’ (AMR) Mixed 2026 Loss Trend Quietly Reframing Its Resilience Story?

In August 2026, Alpha Metallurgical Resources, Inc. reported second-quarter 2026 results showing revenue of US$492.86 million, down from US$550.27 million a year earlier, and a net loss of US$12.25 million versus US$4.95 million, with basic and diluted loss per share from continuing operations widening to US$0.96 from US$0.38. For the first half of 2026, however, revenue declined modestly to US$1,017.84 million from US$1,082.23 million while the net loss narrowed to US$23.28 million from...
NasdaqGS:SFD
NasdaqGS:SFDFood

Smithfield Foods (SFD) Stock Trades Below Fair Value After A 10% Fall

Smithfield Foods stock has fallen around 9.9% over the past week, yet both its Discounted Cash Flow (DCF) intrinsic value estimate and earnings multiples still point to the shares trading below what the fundamentals suggest. The share price declined about 9.9% over the last seven days, which has made the recent valuation gap to intrinsic value more pronounced. The key upside driver is the market's view on Smithfield Foods' ability to keep converting revenue into reliable cash flows. Any...
NasdaqCM:DNTH
NasdaqCM:DNTHBiotechs

Dianthus Therapeutics (DNTH) Climbed, What Is Behind The Move?

Dianthus Therapeutics (DNTH) has drawn fresh attention after reporting a second quarter net loss of US$50.22 million and unveiling DNTH312, a first in class bifunctional fusion protein targeting autoimmune disease pathways. See our latest analysis for Dianthus Therapeutics. The latest DNTH312 announcement and second quarter update come after a period of strong momentum in Dianthus Therapeutics’ stock, with a 30 day share price return of 13.96% and a 90 day share price return of 31.72%. The...
NasdaqGS:HUMA
NasdaqGS:HUMABiotechs

Is Humacyte (HUMA) Undervalued Following Q2 2026 Earnings And Dialysis Trial Data?

Q2 2026 earnings put Humacyte stock back in focus Humacyte (HUMA) has moved back into the spotlight after reporting second quarter 2026 results, with modest revenue and a sizeable quarterly loss prompting investors to reassess the stock’s risk and potential. See our latest analysis for Humacyte. The Q2 2026 loss, the recent Nasdaq minimum bid price notice and the interim Phase III dialysis data have all landed against a weak backdrop for Humacyte. The stock has a 1 day share price return of...
NYSE:DOLE
NYSE:DOLEFood

Kenvue Stock And 2 Consumer Staples Picks For Defensive Dividend Investors

With real wages squeezed by stubborn inflation and household budgets under pressure, investors are paying closer attention to companies tied to everyday essentials. Consumer staples stocks in our U.S. screener sit right in the middle of this story, where price sensitivity, volume trends and cost control all matter. This article walks through 3 stocks that appear positively exposed to this backdrop and explains why each might deserve a place on your watchlist. The stocks covered below are only...
NasdaqGM:OLLI
NasdaqGM:OLLIMultiline Retail

TJX Stock Leads 3 Discount Retail Picks As Inflation Keeps Shoppers Trading Down

Inflation is cooling but not gone, the Fed looks cautious, and everyday costs from flights to food keep squeezing household budgets. That mix can push shoppers toward discount and value-focused brands, which may help some stocks tied to this trend while leaving others exposed to pressure. This article looks at three stocks linked to the recent CPI backdrop and explains how the same data can create very different stories for investors. The three stocks below are just a starting sample, and the...
NYSE:OII
NYSE:OIIEnergy Services

Oceaneering International (OII) Stock Looks Reasonable Near Fair Value

Oceaneering International has delivered a very strong 336.8% return over the past 5 years, yet its valuation checks and market signals now suggest the stock may no longer be an obvious bargain, with an intrinsic value estimate from a Discounted Cash Flow (DCF) model pointing to a price that is close to where the shares currently trade. A 336.8% total return over 5 years highlights how much value the market has already priced into Oceaneering International, which raises the bar for any...
NYSE:MCK
NYSE:MCKHealthcare

Surging Sales, Falling EPS, and Big Buybacks Could Be A Game Changer For McKesson (MCK)

In early August 2026, McKesson Corporation reported first-quarter sales of US$105.38 billion, up from US$97.83 billion a year earlier, while net income fell to US$614 million and diluted EPS from continuing operations declined to US$5.15 from US$6.25. Over the same quarter, McKesson repurchased 3,600,000 shares for US$2,896.30 million, bringing total buybacks under its long-running program to 70,100,000 shares for US$23,475.49 million, significantly shrinking its share count and reshaping...
NasdaqGM:SION
NasdaqGM:SIONBiotechs

Is Sionna Therapeutics (SION) Undervalued After SION 719 Failed And Development Was Halted?

Sionna Therapeutics (SION) is back in focus after reporting Phase 2a data showing that lead cystic fibrosis candidate SION-719 missed its key efficacy endpoint as an add-on to Trikafta, prompting the company to halt development. See our latest analysis for Sionna Therapeutics. The failed Phase 2a readout for SION-719 has been followed by sharp share price volatility, with Sionna Therapeutics’ stock down 86.8% on a 7 day share price return and 84.1% on a year to date share price return, while...
NYSE:NNN
NYSE:NNNRetail REITs

NNN REIT (NNN) Stock May Be 45% Below Fair Value On Cash Flow

NNN REIT has delivered a 40.2% return over the past three years, and the current share price of US$45.81 still screens as cheap relative to an intrinsic value estimate based on a Discounted Cash Flow (DCF) model and traditional multiples. The 40.2% gain over three years suggests investors have already seen solid value creation, yet current indicators still point to room between price and estimated worth. Future cash flows from long term, triple net leases can support this valuation view...
NasdaqGS:PENN
NasdaqGS:PENNHospitality

PENN Entertainment (PENN) Stock Looks Cheap On Sales While Online Risks Linger

PENN Entertainment has put long term shareholders through a rough ride, with the share price down about 71% over the past 5 years, yet the stock now screens as cheap on several valuation checks. Recent news around stronger physical casino performance and increased iGaming investment has refocused attention on whether the current price reflects the company’s mix of mature retail assets and a more competitive online business. The roughly 71% share price decline over 5 years leaves PENN...
NYSE:CLVT
NYSE:CLVTProfessional Services

Does Clarivate’s Expanded Agentic AI Across Cortellis Reshape the Bull Case For Clarivate (CLVT)?

In August 2026, Clarivate Plc expanded agentic AI capabilities across its Cortellis life sciences portfolio, embedding AI into drug discovery, safety assessment and portfolio decision workflows to reduce manual effort and support faster, evidence-based decisions. By integrating multi-agent AI directly into Cortellis tools like Drug Discovery Intelligence, OFF-X and Competitive Intelligence, Clarivate is turning previously time-intensive R&D and market analysis tasks into higher-value,...
NasdaqGS:LECO
NasdaqGS:LECOMachinery

Is Lincoln Electric Holdings (LECO) Undervalued On Strong Earnings And Buybacks?

Lincoln Electric Holdings (LECO) has drawn fresh attention after reporting second quarter and first half 2026 results that showed higher year-on-year sales and net income, alongside continued progress on its multi year share repurchase program. See our latest analysis for Lincoln Electric Holdings. Lincoln Electric Holdings’ recent earnings update and ongoing buybacks appear to have supported sentiment, with a 14.24% 1 month share price return and a 17.73% year to date share price return. The...
NYSE:SCI
NYSE:SCIConsumer Services

Service Corporation International (SCI) Stock Looks Fairly Valued As Shares Rose 43%

Service Corporation International has delivered a 42.8% share price gain over the past three years, yet its valuation checks look mixed, with an intrinsic value estimate from a Discounted Cash Flow (DCF) model indicating meaningful upside relative to the current US$84.40 share price. Over the last three years, Service Corporation International shares are up 42.8%, which puts recent returns in focus when judging whether the stock still offers value. Future cash flow expectations and the...
NasdaqGM:ETON
NasdaqGM:ETONPharmaceuticals

What Could Eton Pharmaceuticals (ETON) Gain From The ASN 001 Licensing Deal?

Eton Pharmaceuticals (NasdaqGM: ETON) licensed U.S. rights to ASN-001, a potential first FDA-approved topical therapy for infantile hemangiomas, from Auson Pharmaceuticals. The agreement centers on ASN-001, which targets an unmet need in pediatric dermatology where no FDA-approved topical treatments for infantile hemangiomas are currently available. Eton plans to leverage its existing pediatric dermatology infrastructure, including HEMANGEOL, to support development and potential...
NYSE:SW
NYSE:SWPackaging

How Smurfit Westrock’s US$100 Price Hike for Containerboard Will Impact Smurfit Westrock (SW) Investors

Smurfit Westrock previously announced it would raise containerboard prices by US$100 per tonne from 1 September 2026, following several earlier hikes across major producers and drawing criticism from the AICC, which argued these increases were not justified by raw material costs or broader economic conditions. This push to lift containerboard pricing highlights the company’s ongoing effort to enhance revenue quality and profitability against a backdrop of questioned industry-wide pricing...
NYSE:LION
NYSE:LIONEntertainment

Lionsgate Studios (LION) Faces Public Pressure To Recast Its Business For AI

Activist investor Anson Funds is publicly urging Lionsgate Studios (NYSE:LION) to reshape its business for the AI era or consider a sale. The firm is questioning how Lionsgate Studios communicates the value of its film library and broader assets to investors as generative AI changes the media sector. The campaign could influence Lionsgate Studios' future direction, including possible M&A discussions and new approaches to monetizing content with AI tools. Lionsgate Studios is not the only...
NasdaqGS:DRH
NasdaqGS:DRHHotel and Resort REITs

Why Everyone Is Watching DiamondRock Hospitality (DRH) Right Now

DiamondRock Hospitality (DRH) has investors’ attention after its second quarter 2026 update, which combined stronger earnings, a higher dividend and an active capital return program. The company also flagged interest in acquisition opportunities. See our latest analysis for DiamondRock Hospitality. DiamondRock Hospitality’s share price has climbed 34.1% year to date and 16.5% over the past 90 days, while its 1 year total shareholder return of 57.9% points to strengthening momentum as recent...
NasdaqGS:IBOC
NasdaqGS:IBOCBanks

Did Steady H1 Earnings and a Higher Dividend Just Recast International Bancshares' (IBOC) Investment Narrative?

International Bancshares Corporation has reported past second-quarter 2026 results, with net interest income rising to US$171.11 million while quarterly net income eased to US$95.81 million and earnings per share from continuing operations dipped to US$1.54. Despite the softer quarter, the first half of 2026 showed relatively steady profitability and the board approved a US$0.73 per-share cash dividend, underscoring the bank’s continued capital return to shareholders. Next, we examine how...